Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with Rifaximin

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 21

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

595

HTML

8186

Figures (1-1)

475

Tables (1-1)

406

Sum=9662

Jun 7, 2009 (publication date) through Oct 30, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Articles

World J Gastroenterol. Jun 7, 2009; 15(21): 2628-2631
Published online Jun 7, 2009. doi: 10.3748/wjg.15.2628

Table 1 Demographic characteristics of patients with a new diagnosis of IBS (n = 97)

Demographic characteristics	n	Breath test at screening
Demographic characteristics	n	Positive (n = 54)	Negative (n = 43)
Sex (M/F, mean ± SD)	40/57 (40.7 ± 16.2)
IBS variants n (%)
Chronic diarrhoea	31 (31.9)	19 (35.2)	12 (27.9)
Stipsis	20 (20.6)	11 (20.4)	9 (20.9)
Alternated stipsis/diarrhoea	46 (47.5)	24 (44.4)	22 (51.2)
Symptoms score
Chronic diarrhoea	2.2 ± 0.8	2.2 ± 0.7	2.1 ± 0.6
Stipsis	2.3 ± 0.9	2.4 ± 0.8	2.1 ± 0.9
Alternated stipsis/diarrhoea	2.0 ± 1.2	2.3 ± 0.9	1.7 ± 0.6^a

^aStatistically significant difference between groups, P = 0.019.

Citation: Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with Rifaximin. World J Gastroenterol 2009; 15(21): 2628-2631
URL: https://www.wjgnet.com/1007-9327/full/v15/i21/2628.htm
DOI: https://dx.doi.org/10.3748/wjg.15.2628